No.2
😒🚬
🈁The stock price of Celcuity Inc (NASDAQ: CELC) – a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer – increased by over 30% pre-market. This is why it happened.
Investors appear to be responding to Celcuity announcing that it has entered into a global licensing agreement with Pfizer Inc. (NYSE:PFE) – which granted Celcuity exclusive rights to Pfizer’s gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor.
時価総額小さいし寄りから買ってみよう🤭
返信
投資の参考になりましたか？
